LEUKINE

(Leukine)

Phase 2Small molecule

PPartner Therapeutics, Inc.

LEUKINE is one of 50 small molecule programs targeting Pulmonary Alveolar Proteinosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Pulmonary Alveolar ProteinosisActive, not recruiting

Renal Cell CarcinomaActive, not recruiting

Pulmonary Alveolar ProteinosisPhase 2

Active, not recruiting

Renal Cell CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

363 competitors in Renal Cell Carcinoma

#DrugCompanyPhaseTrials

Cabometyx

Bristol-Myers Squibb

Phase 3

31 2

Votrient

Novartis

Phase 3

25 3

Nexavar

Bayer

Phase 3

23 4

Inlyta

PPrism Pharmaceuticals

Phase 3

27 5

Tecentriq

Roche

Phase 3

8 6

Imjudo

AstraZeneca

Phase 3

3 7

Imfinzi

AstraZeneca

Phase 3

2 8

Depo-Provera

Eli Lilly

Phase 3

1 9

TKI258

Novartis

Phase 3

1 10

Roferon-a

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Critical Illness1 trial

Does GM-CSF Restore Neutrophil Phagocytosis in Critical Illness?

Completed·NNewcastle-upon-Tyne Hospitals NHS Trust·Phase 1/2·NCT01653665·64 enrolled

Pulmonary Alveolar Proteinosis1 trial

Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)

Completed·—·Phase 2·NCT01511068·2 enrolled

Renal Cell Carcinoma1 trial

Randomized Phase 2 Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in Combination With Gemzar & 5-FU in Patients With Metastatic Renal Cell Carcinoma

Withdrawn·UUniversity of Kentucky·Phase 2·NCT00176280

Regulatory

FDA Approval Timeline[4]

Mar 5, 1991

LEUKINE

BLA BLA103362

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Leukine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Leukine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Leukine. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA103362). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Partner Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPartner Therapeutics, Inc.

LEUKINE

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Critical Illness1 trial

Pulmonary Alveolar Proteinosis1 trial

Renal Cell Carcinoma1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News